Functional Screening and Drug Target Discovery
Cellecta Inc. provides custom and contract solutions for high-throughput genetic screening needs. Our research organization focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches that identify the mechanisms regulating biological processes to expedite the discovery and characterization of novel therapeutic targets and drugs.
The unique capabilities of lentiviral and shRNA technologies provide a platform that enables genome-wide functional screening and the identification and validation of genes involved in critical biological and pathological responses.
- shRNA Loss-of-Function Screen Identifies Alternate Pathway for BCR-ABL1 Kinase-independent Resistance in Chronic Myeloid Leukemia March 30, 2015
- CRISPR Knockout Screens with Optimal Cas9 to sgRNA Ratios March 12, 2015
- Two-Vector CRISPR System Is Better Approach for Knockout Screens November 26, 2014
Cellecta, partnered with Agilent Technologies, the Roswell Park Cancer Institute, FHCRC, TSRI, and Illumina, has created one of the most advanced, effective, and reliable pooled shRNA library platforms available. We also offer pooled bioactive peptide libraries.